|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
2
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, et al: Prognostic factors in high-grade osteosarcoma of
the extremities or trunk: an analysis of 1,702 patients treated on
neoadjuvant cooperative osteosarcoma study group protocols. J Clin
Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kansara M and Thomas DM: Molecular
pathogenesis of osteosarcoma. DNA Cell Biol. 26:1–18. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marulanda GA, Henderson ER, Johnson DA,
Letson GD and Cheong D: Orthopedic surgery options for the
treatment of primary osteosarcoma. Cancer Control. 15:13–20.
2008.
|
|
5
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calin GA, Dumitru CD, Shimizu M, et al:
Frequent deletions and down-regulation of micro- RNA genes miR15
and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad
Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ruvkun G: Clarifications on miRNA and
cancer. Science. 311:36–37. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garofalo M, Di Leva G, Romano G, et al:
miR-221&222 regulate TRAIL resistance and enhance
tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell.
16:498–509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Acunzo M, Visone R, Romano G, et al:
miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by
downregulating miR-221 and 222. Oncogene. 31:634–642. 2012.
|
|
11
|
Garofalo M, Romano G, Di Leva G, et al:
EGFR and MET receptor tyrosine kinase-altered microRNA expression
induces tumorigenesis and gefitinib resistance in lung cancers. Nat
Med. 18:74–82. 2011.PubMed/NCBI
|
|
12
|
Reinhart BJ, Slack FJ, Basson M,
Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G:
The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takamizawa J, Konishi H, Yanagisawa K, et
al: Reduced expression of the let-7 microRNAs in human lung cancers
in association with shortened postoperative survival. Cancer Res.
64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Johnson SM, Grosshans H, Shingara J, et
al: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee YS and Dutta A: The tumor suppressor
microRNA let-7 represses the HMGA2 oncogene. Genes Dev.
21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Akao Y, Nakagawa Y and Naoe T: let-7
microRNA functions as a potential growth suppressor in human colon
cancer cells. Biol Pharm Bull. 29:903–906. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Attwooll C, Lazzerini Denchi E and Helin
K: The E2F family: specific functions and overlapping interests.
EMBO J. 23:4709–4716. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Trimarchi JM and Lees JA: Sibling rivalry
in the E2F family. Nat Rev Mol Cell Biol. 3:11–20. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dimova DK and Dyson NJ: The E2F
transcriptional network: old acquaintances with new faces.
Oncogene. 24:2810–2826. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wong JV, Dong P, Nevins JR, Mathey-Prevot
B and You L: Network calisthenics: control of E2F dynamics in cell
cycle entry. Cell Cycle. 10:3086–3094. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Helin K: Regulation of cell proliferation
by the E2F transcription factors. Curr Opin Genet Dev. 8:28–35.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aguda BD, Kim Y, Piper-Hunter MG, Friedman
A and Marsh CB: MicroRNA regulation of a cancer network:
consequences of the feedback loops involving miR-17–92, E2F, and
Myc. Proc Natl Acad Sci USA. 105:19678–19683. 2008. View Article : Google Scholar
|
|
23
|
Lal A, Navarro F, Maher CA, et al: miR-24
Inhibits cell proliferation by targeting E2F2, MYC, and other
cell-cycle genes via binding to ‘seedless’ 3′UTR microRNA
recognition elements. Mol Cell. 35:610–625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nelson KM and Weiss GJ: MicroRNAs and
cancer: past, present, and potential future. Mol Cancer Ther.
7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu X, Guo J, Zheng L, et al: The
heterochronic microRNA let-7 inhibits cell motility by regulating
the genes in the actin cytoskeleton pathway in breast cancer. Mol
Cancer Res. 11:240–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang Q, Jie Z, Cao H, Greenlee AR, Yang C,
Zou F and Jiang Y: Low-level expression of let-7a in gastric cancer
and its involvement in tumorigenesis by targeting RAB40C.
Carcinogenesis. 32:713–722. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen C and Wells AD: Comparative analysis
of E2F family member oncogenic activity. PLoS One. 2:e9122007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin PC, Chiu YL, Banerjee S, et al:
Epigenetic repression of miR-31 disrupts androgen receptor
homeostasis and contributes to prostate cancer progression. Cancer
Res. 73:1232–1244. 2013. View Article : Google Scholar :
|
|
29
|
Fujiwara K, Yuwanita I, Hollern DP and
Andrechek ER: Prediction and genetic demonstration of a role for
activator E2Fs in Myc-induced tumors. Cancer Res. 71:1924–1932.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Okamoto OK, Oba-Shinjo SM, Lopes L and
Nagahashi Marie SK: Expression of HOXC9 and E2F2 are up-regulated
in CD133+ cells isolated from human astrocytomas and
associate with transformation of human astrocytes. Biochim Biophys
Acta. 1769:437–442. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dong Q, Meng P, Wang T, et al: MicroRNA
let-7a inhibits proliferation of human prostate cancer cells in
vitro and in vivo by targeting E2F2 and CCND2. PLoS One.
5:e101472010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sharma N, Timmers C, Trikha P, Saavedra
HI, Obery A and Leone G: Control of the p53-p21CIP1 Axis by E2f1,
E2f2, and E2f3 is essential for G1/S progression and cellular
transformation. J Biol Chem. 281:36124–36131. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nguyen-Vu T, Vedin LL, Liu K, et al: Liver
x receptor ligands disrupt breast cancer cell proliferation through
an E2F-mediated mechanism. Breast Cancer Res. 15:R512013.
View Article : Google Scholar
|
